ANIP ANI PHARMACEUTICALS INC

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: developing, manufacturing, commercializing therapeutics via Rare Disease, Generics, and Brands segments
• • Acquired Alimera Sciences on September 16, 2024, adding ILUVIEN® and YUTIQ® products
• • Strategic expansion into ophthalmic specialty products through acquisition
• • Acquisition introduces new product lines, diversifying portfolio beyond prior scope

Risk Factors

• • Regulatory/legal risk: Compliance with Medicaid Drug Rebate Program risks material penalties due to increased rebate accruals from branded and authorized generic products
• • Geopolitical/macro risk: 17% of raw materials/API from one domestic supplier in 2025; supply disruption risk from FDA inspections and trade or geopolitical tensions
• • Operational/supply chain risk: Reliance on single-source third-party contract manufacturers for Cortrophin Gel and ILUVIEN, risking commercialization delays if noncompliant or unavailable
• • Competitive risk: Dependence on Cortrophin Gel, competing with major pharma companies and generics that may have fewer side effects and higher physician acceptance
• • Financial/structural risk: 2024 Credit Agreement contains restrictive financial covenants, with potential for accelerated debt repayment and termination if breached

Management Discussion & Analysis

• • Total revenue details not provided for FY 2024; Alimera acquisition adds ILUVIEN® and YUTIQ® franchises
• • No specific operating margin or profitability figures mentioned in the available excerpt
• • No segment-specific revenue or profit data disclosed
• • Sale of Oakville facility for $14.2 million completed in March 2024; no other cash flow or capital allocation details given
• • Management highlights growth via ILUVIEN label expansion and Alimera acquisition; no formal guidance or risk outlook stated

What are the latest ANIP SEC filings in 2026?

ANI PHARMACEUTICALS INC (ANIP) has filed a 10-K annual report on February 27, 2026, a 10-Q quarterly report on May 8, 2026, an 8-K current report on August 7, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did ANIP file its most recent 10-K annual report?

ANI PHARMACEUTICALS INC (ANIP) filed its most recent 10-K annual report on February 27, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view ANIP 10-Q quarterly reports?

ANI PHARMACEUTICALS INC (ANIP)'s most recent 10-Q quarterly report was filed on May 8, 2026. SignalX displays every ANIP 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has ANIP filed recently?

ANI PHARMACEUTICALS INC (ANIP)'s most recent 8-K was filed on August 7, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find ANIP insider trading activity (Form 4)?

SignalX aggregates every ANIP Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does ANIP file with the SEC?

ANI PHARMACEUTICALS INC (ANIP) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ANIP filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for ANI PHARMACEUTICALS INC (ANIP).

What is ANIP's SEC CIK number?

ANI PHARMACEUTICALS INC (ANIP)'s SEC CIK (Central Index Key) number is 1023024. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1023024 to look up all ANIP filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find ANIP return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from ANI PHARMACEUTICALS INC (ANIP) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.